Manufacturing

Articles

Samsung Biologics is planning to construct a new manufacturing facility in Incheon, South Korea, that will offer multi-product manufacturing, including cell and gene therapies and next-gen vaccines.

Samsung Biologics to Construct New Manufacturing Facility for Next-Gen Vaccines and CGT

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

Feliza Mirasol is the science editor for 

Enhancement of resin technology can improve the ability of chromatography to purify the growing landscape of increasingly complex biomolecules.

Enhancing Resins Addresses Purification Concerns

SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.

New Isolator for Cell and Gene Therapy Manufacturing

Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.

Leucid Bio to Use Lonza’s Cocoon Platform for Automated Manufacturing of CAR T Cells

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Timing is everything, and it might be ideal for acceleration of real-time monitoring solutions. 

Process Analytical Technologies for Manufacturing Cell and Gene Therapies

Raymond P. Goodrich, PhD, is the founder of PhotonPharma, executive director of the infectious disease research center at Colorado State University, and professor for the department of microbiology, immunology, and pathology at Colorado State University.

Amanda Guth, DVM, PhD, is the chief scientific officer for PhotonPharma.

Jon Weston is the president and CEO of PhotonPharma.

Terry Opgenorth, PhD, is the executive in residence life sciences for CSU Ventures.

Gary Gordon, MD, PhD, is the president of Global Coalition for Adaptive Research.

Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.

Formulating Autologous Therapies for Cancer

Editor of Pharmaceutical Technology Europe

Scientific innovation and regulatory reformations are helping to drive the global biopharma market forward, but a balance between cost and value still needs to be accepted for widespread adoption.

Finding the Right Balance for Advanced Therapies

Chris Spivey is the editorial director of 

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Manufacturing, Cell Therapies